Hurdles for Phage Therapy (PT) to Become a Reality
Alternative treatment modes for antibiotic-resistant bacterial pathogens have become a public health priority. Bacteriophages are bacterial viruses that infect and lyse bacterial cells. Since bacteriophages are frequently bacterial host species-specific and can often also infect antibiotic-resistant...
Saved in:
: | |
---|---|
Year of Publication: | 2019 |
Language: | English |
Physical Description: | 1 electronic resource (484 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993548811304498 |
---|---|
ctrlnum |
(CKB)4100000010106080 (oapen)https://directory.doabooks.org/handle/20.500.12854/49693 (EXLCZ)994100000010106080 |
collection |
bib_alma |
record_format |
marc |
spelling |
Brüssow, Harald auth Hurdles for Phage Therapy (PT) to Become a Reality Hurdles for Phage Therapy MDPI - Multidisciplinary Digital Publishing Institute 2019 1 electronic resource (484 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Alternative treatment modes for antibiotic-resistant bacterial pathogens have become a public health priority. Bacteriophages are bacterial viruses that infect and lyse bacterial cells. Since bacteriophages are frequently bacterial host species-specific and can often also infect antibiotic-resistant bacterial cells, they could represent ideal antimicrobials for fighting the antibiotic resistance crisis. The medical use of bacteriophages has become known as phage therapy. It is widely used in Russia, where phage cocktails are sold in pharmacies as an over-the-counter drug. However, no phage product has been registered for medical purposes outside of the former Soviet Union. The current Special Issue of Viruses contains a collection of papers from opinion leaders in the field who explore hurdles to the introduction of phage therapy in western countries. The articles cover diverse topics ranging from patent to regulatory issues, the targeting of suitable bacterial infections, and the selection and characterization of safe and efficient phage cocktails. Phage resistance is discussed, and gaps in our knowledge of phage–bacterium interactions in the mammalian body are revealed, while other articles explore the use of phages in food production and processing. English alginate abortive infection bacterial resistance bacteriophages ATMP MALDI-MS adaptation Bacteriophage horizontal gene transfer adaptive immunity co-evolution Listeria ivanovii personalised medicines pH stability phage-human host interaction vB_SauM-fRuSau02 antimicrobial resistance phagodisinfection biofilm capsule depolymerase animal model phage cocktails Enterococcus cases report zoonosis resistance magistral formula experimental therapy Belgium phage therapy E. faecalis nontraditional antibacterial industrial phage application Democratic Republic of the Congo OrthoMCL Germany high-throughput sequencing antimicrobial infection antibiotic therapy Kayvirus phages Twortlikevirus bacterial disease human host Pseudomonas aeruginosa phage multidrug-resistant bacteria bacterial infection Salmonella Typhi rhamnopolysaccharide compassionate use crop production compounding pharmacy antimicrobial resistance (AMR) best practices bacteriophage efficacy phage sensitivity antibiotic-resistance antibiotic lysins PTMP Escherichia coli typhoid fever patent landscape phage preparation innate immunity anti-phage antibodies immunology Staphylococcus aureus global health clinical trial adsorption Brussels phage-resistance Galleria mellonella science communication history of science virus-host interactions foodborne illness prophage resistance management biofilms IND immunomodulation frequency of resistance capsule gastrointestinal tract phage-host interactions disinfection production bacteriophage therapy bacteriophage Staphylococcus magistral preparation extended-spectrum beta lactamases (ESBL) Viral proteins antibiotic resistance genomics phage biocontrol therapy target selection viral genomes evolution pharmaceutical paradigm shift personalized medicine pharmaceutical legislation food safety regulation virulence developing countries infectious disease regulatory framework sustainable agriculture Klebsiella pneumoniae 3-03921-391-1 |
language |
English |
format |
eBook |
author |
Brüssow, Harald |
spellingShingle |
Brüssow, Harald Hurdles for Phage Therapy (PT) to Become a Reality |
author_facet |
Brüssow, Harald |
author_variant |
h b hb |
author_sort |
Brüssow, Harald |
title |
Hurdles for Phage Therapy (PT) to Become a Reality |
title_full |
Hurdles for Phage Therapy (PT) to Become a Reality |
title_fullStr |
Hurdles for Phage Therapy (PT) to Become a Reality |
title_full_unstemmed |
Hurdles for Phage Therapy (PT) to Become a Reality |
title_auth |
Hurdles for Phage Therapy (PT) to Become a Reality |
title_alt |
Hurdles for Phage Therapy |
title_new |
Hurdles for Phage Therapy (PT) to Become a Reality |
title_sort |
hurdles for phage therapy (pt) to become a reality |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2019 |
physical |
1 electronic resource (484 p.) |
isbn |
3-03921-392-X 3-03921-391-1 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT brussowharald hurdlesforphagetherapypttobecomeareality AT brussowharald hurdlesforphagetherapy |
status_str |
n |
ids_txt_mv |
(CKB)4100000010106080 (oapen)https://directory.doabooks.org/handle/20.500.12854/49693 (EXLCZ)994100000010106080 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Hurdles for Phage Therapy (PT) to Become a Reality |
_version_ |
1796649014342451201 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05914nam-a2201657z--4500</leader><controlfield tag="001">993548811304498</controlfield><controlfield tag="005">20231214132829.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2019 xx |||||o ||| 0|eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3-03921-392-X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4100000010106080</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/49693</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994100000010106080</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Brüssow, Harald</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hurdles for Phage Therapy (PT) to Become a Reality</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Hurdles for Phage Therapy </subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (484 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Alternative treatment modes for antibiotic-resistant bacterial pathogens have become a public health priority. Bacteriophages are bacterial viruses that infect and lyse bacterial cells. Since bacteriophages are frequently bacterial host species-specific and can often also infect antibiotic-resistant bacterial cells, they could represent ideal antimicrobials for fighting the antibiotic resistance crisis. The medical use of bacteriophages has become known as phage therapy. It is widely used in Russia, where phage cocktails are sold in pharmacies as an over-the-counter drug. However, no phage product has been registered for medical purposes outside of the former Soviet Union. The current Special Issue of Viruses contains a collection of papers from opinion leaders in the field who explore hurdles to the introduction of phage therapy in western countries. The articles cover diverse topics ranging from patent to regulatory issues, the targeting of suitable bacterial infections, and the selection and characterization of safe and efficient phage cocktails. Phage resistance is discussed, and gaps in our knowledge of phage–bacterium interactions in the mammalian body are revealed, while other articles explore the use of phages in food production and processing.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">alginate</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">abortive infection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bacterial resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bacteriophages</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ATMP</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MALDI-MS</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adaptation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Bacteriophage</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">horizontal gene transfer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adaptive immunity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">co-evolution</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Listeria ivanovii</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">personalised medicines</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pH stability</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phage-human host interaction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">vB_SauM-fRuSau02</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antimicrobial resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phagodisinfection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biofilm</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">capsule depolymerase</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">animal model</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phage cocktails</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Enterococcus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cases report</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">zoonosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">magistral formula</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">experimental therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Belgium</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phage therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">E. faecalis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nontraditional antibacterial</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">industrial phage application</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Democratic Republic of the Congo</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">OrthoMCL</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Germany</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">high-throughput sequencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antimicrobial</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">infection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibiotic therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Kayvirus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phages</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Twortlikevirus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bacterial disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">human host</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Pseudomonas aeruginosa</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phage</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">multidrug-resistant bacteria</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bacterial infection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Salmonella Typhi</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">rhamnopolysaccharide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">compassionate use</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">crop production</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">compounding pharmacy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antimicrobial resistance (AMR)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">best practices</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bacteriophage efficacy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phage sensitivity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibiotic-resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibiotic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lysins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PTMP</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Escherichia coli</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">typhoid fever</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">patent landscape</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phage preparation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">innate immunity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anti-phage antibodies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Staphylococcus aureus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">global health</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical trial</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adsorption</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Brussels</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phage-resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Galleria mellonella</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">science communication</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">history of science</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">virus-host interactions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">foodborne illness</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prophage</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">resistance management</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biofilms</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">IND</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunomodulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">frequency of resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">capsule</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gastrointestinal tract</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phage-host interactions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">disinfection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">production</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bacteriophage therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bacteriophage</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Staphylococcus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">magistral preparation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">extended-spectrum beta lactamases (ESBL)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Viral proteins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibiotic resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phage biocontrol</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">target selection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">viral genomes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">evolution</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pharmaceutical paradigm shift</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">personalized medicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pharmaceutical legislation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">food safety</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">regulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">virulence</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">developing countries</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">infectious disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">regulatory framework</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sustainable agriculture</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Klebsiella pneumoniae</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03921-391-1</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:32:38 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2020-02-01 22:26:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338895950004498&Force_direct=true</subfield><subfield code="Z">5338895950004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338895950004498</subfield></datafield></record></collection> |